Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2009
05/22/2009WO2005020913A3 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
05/22/2009CA2743756A1 Inhibitors of pim protein kinases, compositions, and methods for treating cancer
05/22/2009CA2706549A1 Monoclonal antibody capable of binding to anexelekto, and use thereof
05/22/2009CA2705922A1 Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
05/22/2009CA2705916A1 Benzazepinone compound
05/22/2009CA2705884A1 New extracts of deschampsia antarctica desv. with antineoplastic activity
05/22/2009CA2705820A1 Quinoline derivatives and their use as tyrosine kinase inhibitors
05/22/2009CA2705812A1 Brca1-based breast or ovarian cancer prevention agents and methods of use
05/22/2009CA2705539A1 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
05/22/2009CA2705537A1 Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
05/22/2009CA2705509A1 Diagnosis and treatment of cancer using anti-gpr49 antibody
05/22/2009CA2705488A1 Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
05/22/2009CA2705481A1 Cephalomannine derivatives, their preparation, pharmaceutical composition and use thereof
05/22/2009CA2705452A1 Mapk/erk kinase inhibitors
05/22/2009CA2705417A1 Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
05/22/2009CA2705391A1 Methods for identification of jak kinase interacting molecules and for the purification of jak kinases
05/22/2009CA2705353A1 Methods of treating cancer using anti cd24 antibodies
05/22/2009CA2705292A1 Humanized antibodies against tl1a
05/22/2009CA2705164A1 Axl antibodies
05/22/2009CA2704599A1 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
05/22/2009CA2704258A1 Novel thermosensitive liposomes containing therapeutic agents
05/22/2009CA2703600A1 N-containing heterocyclic compounds
05/21/2009US20090131527 Novel anthranilic acid derivatives and chloride channel blocking agent containing the same
05/21/2009US20090131511 Palmarumycin based inhibitors of thioredoxin and methods of using same
05/21/2009US20090131506 protein kinase activators or inhibitors such as 3-(Amino-phenyl-methylene)-6-chloro-1,3-dihydro-indol-2-one,used for the treatment of cancer, tumors, atherosclerosis, vision defects, diabetic retinopathy and inflammatory diseases
05/21/2009US20090131505 chronic lymphocytic leukemia or acute lymphoblastic leukemia; use of specific compound (1R)-cyclopropanecarboxylic acid {2-[2-carbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-7-chloro-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
05/21/2009US20090131502 Biologically active compounds
05/21/2009US20090131500 Porphyrin derivates and their use as photosensitizers in photodynamic therapy
05/21/2009US20090131487 calixarenes having acyclic isophthalic acid groups attached, used as target for platelet derived growth factors or vascular endothelial growth factors, angiogenesis inhibitors, antiproliferative, antitumor or anticarcinogenic agents
05/21/2009US20090131482 Methyl-benzimidazole derivatives
05/21/2009US20090131468 Bis-(Sulfonylamino) Derivatives in Therapy 065
05/21/2009US20090131463 Novel compounds
05/21/2009US20090131461 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity
05/21/2009US20090131458 Compounds
05/21/2009US20090131456 Caspase inhibitors and uses thereof
05/21/2009US20090131445 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents
05/21/2009US20090131436 Pyrimidine Derivatives
05/21/2009US20090131429 Pharmaceutical compounds
05/21/2009US20090131428 Benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
05/21/2009US20090131426 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-urea, compositions thereof, and uses therewith
05/21/2009US20090131425 Inhibitors of protein kinases
05/21/2009US20090131423 Tyrosine Kinase Inhibitors
05/21/2009US20090131421 Compounds for proteasome enzyme inhibition
05/21/2009US20090131409 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
05/21/2009US20090131407 Tetracyclic kinase inhibitors
05/21/2009US20090131406 Cropwelllins and synthetic derivatives thereof used as medicaments
05/21/2009US20090131390 FK 228 derivates as HDAC inhibitors
05/21/2009US20090131379 Vitamin d receptor activators and methods of making
05/21/2009US20090131378 Vitamin d derivatives active on the vitamin d nuclear receptor, preparation and uses thereof
05/21/2009US20090131367 Combinations of HDAC Inhibitors and Proteasome Inhibitors
05/21/2009US20090131365 Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
05/21/2009US20090131357 Compositions and methods for preventing and treating cancer via modulating UBE1L, ISG15 and/or UBP43
05/21/2009US20090131353 Using cyclic nucleotide phosphodiesterase profiles as tool in detection of cell proliferative disorders
05/21/2009US20090131348 Micrornas differentially expressed in pancreatic diseases and uses thereof
05/21/2009US20090131317 Compounds and peptides that bind the trail receptor
05/21/2009US20090131306 Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor
05/21/2009US20090131277 Prostate cancer diagnosis and treatment
05/21/2009US20090130715 Antibodies to CD40
05/21/2009US20090130695 Isolated nucleic acid encoding GEF-H1b polypeptide (Guanine nucleotide exchange factors); diagnosing abnormal cell proliferation and drug screening; measuring phosphorylation by p-21 activated kinase; antitumor agents, anticancer agents
05/21/2009US20090130681 21132, a Human G-protein coupled receptor family member and uses therefor
05/21/2009US20090130237 Process of making purified extract of scutellaria barbata d. don
05/21/2009US20090130229 Antitumor uses of compound
05/21/2009US20090130228 Pharmaceutical combination for the treatment and or chemosensibilization of refractory tumors to anticancer drugs
05/21/2009US20090130209 Novel Pyridazinone Derivatives
05/21/2009US20090130195 Prostate carcinogenesis predictor
05/21/2009US20090130194 Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
05/21/2009US20090130193 Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intraperitoneally
05/21/2009US20090130192 Class iii slrp agonists for the reduction of blood vessel formation
05/21/2009US20090130169 Sterilizing compositions comprising phosphors for converting electromagnetic radiation to uvc radiation and methods for using the same
05/21/2009US20090130126 Dna expression vectors
05/21/2009US20090130125 Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer
05/21/2009US20090130119 Anti-ctla-4 antibody compositions
05/21/2009US20090130118 Scutellaria barbata extract and combinations for the treatment of cancer
05/21/2009US20090130117 Substituted Tetrazole Compounds and Uses Thereof
05/21/2009US20090130105 Compositions that bind multiple epitopes of igf-1r
05/21/2009US20090130101 Anti-cancer therapy with an extract of scutellaria barbata
05/21/2009US20090130100 Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate
05/21/2009US20090130098 Specific therapy using integrin ligands for treating cancer
05/21/2009US20090130097 Quinazolinone Compounds and Methods of Use Thereof
05/21/2009US20090130091 Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
05/21/2009US20090130089 Anti-cd20 antibodies and methods of use
05/21/2009US20090130077 Substituted benzoazole pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders
05/21/2009US20090130076 Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders
05/21/2009US20090130074 Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
05/21/2009US20090130061 Adenovirus vectors containing cell status-specific response elements and methods of use thereof
05/21/2009US20090130054 Apc activators in combination with a cytokine-secreting cell and methods of use thereof
05/21/2009US20090130020 Diagnostic agents for positron emission imaging using f-18 radio-labeled amino-alcohols
05/20/2009EP2060630A2 PCA3, PCA3 genes, and methods of use
05/20/2009EP2060582A1 Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
05/20/2009EP2060565A1 Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
05/20/2009EP2060300A1 C-19 steroids for therapeutic uses
05/20/2009EP2060274A1 Method and device for radiotherapy
05/20/2009EP2060272A2 Vitamin-mitomycin conjugates
05/20/2009EP2060271A1 Liposome and immunostimulating composition comprising the same
05/20/2009EP2060259A1 Medical compositions for intravesical treatment of bladder cancer
05/20/2009EP2059593A2 Treating or preventing cancers over-expressing reg4 or kiaa0101
05/20/2009EP2059520A1 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
05/20/2009EP2059518A2 Salts of benzimidazolyl pyridyl ethers and formulations thereof
05/20/2009EP2059514A2 Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis
05/20/2009EP2059511A1 Sulphoximides as protein kinase inhibitors
1 ... 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 ... 2211